Teva Pharmaceuticals has received FDA approval and launched the first-ever generic version of Saxenda® (liraglutide injection), a significant development in the U.S. market for weight-loss medications. This new generic is the first GLP-1 (glucagon-like peptide-1) product of its kind specifically indicated for weight loss, aiming to meet the rising demand for these types of therapies. The move aligns with Teva's strategic focus on expanding its portfolio of complex generic medicines.

The active ingredient, liraglutide, is a GLP-1 receptor agonist. When used alongside a reduced-calorie diet and increased physical activity, it is prescribed to help patients lose weight and maintain that weight loss over time. The medication is indicated for Adults who have obesity or are overweight with at least one weight-related medical condition and for Pediatric patients between the ages of 12 and 17 who weigh more than 60 kg and have obesity.

According to a Teva representative, this product is the fifth "first-to-market" generic launched by the company this year, reinforcing its position in the generics industry. Saxenda® had annual sales of $165 million as of June 2025, suggesting a strong market for the generic version.

It is important to note that liraglutide injection is not recommended for individuals already taking other GLP-1 receptor agonists. The safety and effectiveness of the medication have not been established for children under 12 years of age or for children aged 12 to 17 with type 2 diabetes